BRISTOL MYERS SQUIBB CO

Bristol-Myers Squibb Company (NYSE: BMY) operates as a global biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines for patients with serious diseases. The company website is www.bms.com.

The company operates in a single segment focused on transformational medicines across oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. Bristol-Myers Squibb's strategy combines the resources and scale of a large pharmaceutical company with the speed and agility typically found in the biotech industry, emphasizing first-in-class and best-in-class marketed products where the company maintains competitive advantages.

The company's significant marketed products include Opdivo, a PD-1 inhibitor for multiple cancer indications; Orencia for rheumatoid arthritis and other conditions; Yervoy for melanoma; Eliquis for stroke risk reduction and venous thromboembolism; Revlimid for multiple myeloma and other hematological malignancies; and CAR-T cell therapies including Breyanzi and Abecma. Newer growth products include Camzyos for hypertrophic cardiomyopathy, Zeposia for multiple sclerosis and ulcerative colitis, Sotyktu for psoriasis, Krazati for KRAS-mutated cancers, and Cobenfy for schizophrenia.

Bristol-Myers Squibb maintains significant manufacturing operations in the United States, Puerto Rico, the Netherlands, Ireland and Switzerland. The company's revenue is geographically distributed with the United States representing approximately 69 percent of revenues, international markets 29 percent, and other sources including royalties and alliance revenues comprising 2 percent. Total revenues were approximately $48.2 billion in 2025.

The company operates a broad pipeline with over 45 unique assets in development across multiple therapeutic areas and modalities including small molecules, biologics, antibody-drug conjugates, CAR-T cell therapies and radiopharmaceutical therapeutics. Bristol-Myers Squibb supplements internal research and development with acquisitions, alliances and collaborative agreements, including recent strategic collaborations with BioNTech and Philochem, and the acquisition of Orbital Therapeutics. Products are sold principally to wholesalers, distributors, specialty pharmacies, hospitals, clinics and government agencies worldwide.